Review · United States
Selank
Reviewed on
Approval and product status
No FDA-approved U.S. Selank product was found in the records checked on August 30, 2026
FDA has separate records for Selank and Selank diacetate, a related chemical form. FDA's compounding page uses the name Selank acetate. These records do not show that a sold or compounded product contains the listed form or matches the product used in a study.
What was measured in people?
- Health results · Limited
- Small studies compared Selank with anxiety medicines. They reported symptom changes. The records reviewed did not include a large repeat study against a placebo.
- Body changes · Limited
- A 52-person study measured changes in links between brain areas. It did not measure a treatment benefit, focus, memory, or daily function.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
FDA warns of possible immune reactions with some ways of using compounded Selank acetate. Peptide clumps or related impurities could cause the reaction. FDA also says important human safety information is missing for this chemical form. Short studies cannot show uncommon or long-term harms. This guide gives no dosing, spray, injection, buying, sourcing, or treatment advice.
Still unknown: These small studies do not show that Selank is a proven anxiety treatment. They also do not prove better focus, memory, sleep, mood, or daily function. Most reports came from Russian research groups. The reports gave few details about whether people or researchers knew the assigned treatment. They also gave little information about longer follow-up or uncommon harms. No large, independent repeat study was found among the records reviewed. No FDA-approved U.S. Selank drug was found. FDA says important human safety information is missing for the Selank acetate form. The reviewed records do not show whether an online or compounded product contains the listed chemical form or matches the product used in a study.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“Selank is FDA-approved in the United States.”
Misleading. No FDA-approved U.S. Selank product was found in the records checked. FDA's chemical record names the substance. It does not approve a drug. The request to add Selank acetate to a compounding list was withdrawn. That request was not approval.
Applies to: United States drug-approval and compounding records checked on August 30, 2026.
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
One study compared Selank with medazepam in 62 people. A second study compared Selank with phenazepam in 60 people with several anxiety-related conditions. Both reported symptom improvement. Neither cited study summary describes a placebo group, and both summaries gave few details about the methods.
A separate study used brain scans in 52 healthy people who received Selank, Semax, or placebo. It found changes in links between some brain areas. It did not test anxiety treatment, focus, memory, or daily function.
Read all Selank fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 8 sources
- FDA substance record for Selank, Selanc, and TP-7
U.S. Food and Drug Administration · Reference · 2026
Source accessed
- FDA current substance record showing the related Selank diacetate form
U.S. Food and Drug Administration · Reference · 2026
Source accessed
- Selank compared with medazepam in 62 people
PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Randomized trial · 2008
Source accessed
- Selank compared with phenazepam in 60 people
PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Human clinical study · 2014
Source accessed
- Phenazepam alone compared with phenazepam plus Selank in 70 people
PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Randomized trial · 2015
Source accessed
- Selank, Semax, and placebo brain-scan study in 52 healthy people
PubMed · Doklady Biological Sciences · Human pharmacology · 2020
Source accessed
- FDA list of withdrawn compounding requests and safety concerns
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Drugs@FDA approved-drug search
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed